Eli Lilly reported early Phase 1 results for VERV-102, a base-editing gene therapy acquired from Verve Therapeutics, showing a 62% reduction in cholesterol levels at a high dose. The company highlighted an absence of treatment-related serious adverse events in the study. The data add to the growing evidence that one-time gene-editing approaches could potentially support long-term LDL reduction, a goal with significant unmet need among patients who struggle to maintain effects from conventional therapies. Lilly framed the program as part of a broader intent to prevent heart disease through durable cholesterol lowering. Because the results are early and the report centers on biochemical measures, the next regulatory and commercial step remains mid-stage testing. Still, the update is notable given Verve’s prior safety-related setback and the attention that gene-editing programs draw from investors and clinicians alike.